Leukapheresis Market Expected to Reach $138.7 Million by 2031

Insights into the Future of the Leukapheresis Market

The leukapheresis market is set to experience considerable growth in the coming years, with projections indicating an increase from approximately USD 90.6 million in 2026 to USD 138.7 million by 2031. This surge reflects a compound annual growth rate (CAGR) of 8.9%, showcasing the growing importance of leukapheresis in various medical applications.

Leukapheresis, a medical procedure employed to separate white blood cells from the blood, is gaining traction not only in treatment settings but also in research applications. Notably, the disposables segment holds a significant market share, accounting for 79.8% in 2025, indicating the essential role of single-use disposable products in maintaining sterility and process standardization. The research applications segment is expected to grow at the highest CAGR of 9.0% during this forecast period, underscoring the method's relevance in advancing cell and gene therapies.

Key Factors Driving Market Growth

Several factors contribute to the anticipated growth of the leukapheresis market. One of the primary drivers is the alarming rise in leukemia cases worldwide. As the prevalence of this disease grows, the demand for effective treatment options, including leukapheresis, has also increased. Moreover, the accelerated development of cell and gene therapy programs is further fueling this market's expansion.

Recent advancements in CAR-T therapy approvals coupled with a burgeoning pipeline of clinical trials focused on T-cells, NK-cells, and dendritic cells are contributing significantly to rising procedure volumes. These developments highlight the pivotal role leukapheresis plays as an initial step in both autologous and allogeneic cell therapy manufacturing processes.

Furthermore, innovation in apheresis technology is propelling the market forward. The trend towards automated, good manufacturing practice (GMP) compliant cell collection platforms, along with rising demand for single-use kits and other consumables, underscores the need for efficiency and safety in clinical practices. Growing investments in specialized cell therapy manufacturing facilities across North America, Europe, and Asia Pacific are also promoting the utilization of leukapheresis.

Market Segmentation

By type, the disposable products segment is projected to maintain the largest market share due to the increasing requirement for standardized procedures and strict contamination controls in healthcare. This rising demand for disposables is particularly evident in cell and gene therapy workflows. Globally, regional markets are experiencing varied growth, with Asia Pacific anticipated to exhibit the highest CAGR of 10.0% during the forecast period.

The academic and research institutes are predicted to contribute significantly to market growth, thanks to their involvement in the development of cutting-edge therapies and substantial government funding aimed at fostering innovation in this sector.

Regional Market Insights

North America has emerged as the leading region in the leukapheresis market, holding a substantial share in 2025. This dominance can be attributed to a robust cell and gene therapy ecosystem, a wide network of apheresis centers, and extensive clinical adoption of leukapheresis as a leading procedure in CAR-T and similar therapies. Key factors that bolster North America's position include active enrollment in clinical trials and substantial investments from the biotech sector.

Major Players in the market

Key companies operating in the leukapheresis market include Terumo BCT, Fresenius Kabi, Haemonetics Corporation, Grifols, and many others. These players are actively involved in enhancing product offerings to align with the evolving demands of cellular therapies.

Conclusion

In summary, the leukapheresis market stands on the brink of significant growth, driven by an increasing prevalence of related medical conditions, technological advancements, and an overall uptick in research and clinical applications. As the healthcare landscape continues to evolve, the leukapheresis market is expected to remain at the forefront, adapting to meet the diverse needs of patients and healthcare providers alike.